Afatinib restrains K-RAS driven lung tumorigenesis

Based on clinical trials using first generation EGFR tyrosine kinase inhibitors (TKI) it became a doctrine that K-RAS mutations drive resistance to EGFR inhibition in non-small cell lung cancer (NSCLC). Conversely, we provide evidence that EGFR signaling is engaged in K-RAS driven lung tumorigenesis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Transl Med
Main Authors: Moll, Herwig P., Pranz, Klemens, Musteanu, Monica, Grabner, Beatrice, Hruschka, Natascha, Mohrherr, Julian, Aigner, Petra, Stiedl, Patricia, Brcic, Luka, Laszlo, Viktoria, Schramek, Daniel, Moriggl, Richard, Eferl, Robert, Moldvay, Judit, Dezso, Katalin, Lopez-Casas, Pedro P., Stoiber, Dagmar, Hidalgo, Manuel, Penninger, Josef, Sibilia, Maria, Győrffy, Balázs, Barbacid, Mariano, Dome, Balázs, Popper, Helmut, Casanova, Emilio
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7610658/
https://ncbi.nlm.nih.gov/pubmed/29925635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aao2301
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados